We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Momenta (MNTA) Earnings and Revenues Lag Estimates in Q2
Read MoreHide Full Article
Shares of Momenta Pharmaceuticals Inc. declined 7.8% after the company reported disappointing second-quarter results, wherein both earnings and revenues lagged estimates.
Momenta’s stock has gained 85.6% in the year so far as against the industry’s decline of 4.2%.
The company reported a loss per share of 91 cents in the quarter, significantly wider than the Zacks Consensus Estimate of 46 cents and the year-ago loss of 50 cents.
Revenues in the quarter came in at $13.0 million, significantly down from $23.6 million in the year-ago quarter and below the Zacks Consensus Estimate of $18.3 million.
Quarter in Detail
Momenta’s top line comprises product revenues of $11.8 million earned from Sandoz’s sales of Glatopa, a generic version of Copaxone (20 mg), compared with $19.1 million in the year-ago quarter. The decrease was a result of lower sales due to market decline and Mylan’s entry into the Copaxone market.
Research and development revenues came in at $1.3 million compared with $4.4 million in the year-ago quarter. The decrease was primarily due to lower revenues recognized from the upfront payment from Mylan compared with the amount recognized in the 2017 period and lower reimbursable expenses for the complex generic programs.
Research and development expenses decreased to $31.3 million from $39.1 million in the year-ago quarter due to a decrease in external R&D expenses for M923. General and administrative expenses were roughly flat at $22.5 million.
During the second quarter, Momenta entered into a contract amendment to an agreement with Human Genome Sciences, Inc., the supplier of product for M923. Per the terms of the agreement, Momenta will pay the latter $30.0 million for the purchase of product batches for M923 through 2022.
Pipeline Updates
In June 2018, Momenta’s partner, Sandoz informed its customers and the FDA that it will be discontinuing the supply of the generic version of Lovenox injection, for the prevention and treatment of deep vein thrombosis, developed in collaboration with Sandoz.
Meanwhile, Momenta and Mylan plan to initiate a patient clinical trial of M710, a proposed biosimilar of Regeneron’s (REGN - Free Report) Eylea, shortly.
The Biologics License Application (“BLA”) for Momenta’s M923, a biosimilar version of Humira, is also ready to be filed with the FDA. However, the filing of the BLA is dependent on the outcome of the company’s ongoing strategic review.
Momenta’s novel auto-immune portfolio includes M230, a Selective Immunomodulator of Fc receptors (SIF3); M281, an anti-FcRn monoclonal antibody; and M254.
Momenta successfully completed a phase I single ascending dose study in healthy volunteers for M281. The company is planning two phase II proof of concept clinical trials in the fourth quarter of 2018, pending regulatory feedback.
Meanwhile, Momenta and collaboration partner CSL began dosing healthy volunteers in the phase I trial to evaluate the safety and tolerability of M230. The study is expected to be completed in 2019.
Momenta completed the IND-enabling toxicology study of M254 and is targeting the initiation of a phase I/II proof of concept study in late 2018 or early 2019, pending regulatory feedback.
Our Take
Momenta’s second-quarter results were dismal as the company lost market share for Glatopa 20 mg. While the FDA approval of Glatopa 40 mg should relieve Momenta, competition will limit market share gains for the company as Mylan has already won the FDA’s approval for a generic version of Teva Pharmaceuticals’ (TEVA - Free Report) Copaxone 40 mg. The company continues to face fierce competition due to growing pricing pressure from Mylan and Teva.
Hence, investors will now mainly focus on the outcome of the strategic review announced earlier this year to address the revenue uncertainty related to the late launch of Glatopa 40 mg and the funding challenges for advancing its broad portfolio. The company is evaluating options for its biosimilars business and might have to sell the business to focus on its novel drug candidates for autoimmune indications.
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Image: Bigstock
Momenta (MNTA) Earnings and Revenues Lag Estimates in Q2
Shares of Momenta Pharmaceuticals Inc. declined 7.8% after the company reported disappointing second-quarter results, wherein both earnings and revenues lagged estimates.
Momenta’s stock has gained 85.6% in the year so far as against the industry’s decline of 4.2%.
The company reported a loss per share of 91 cents in the quarter, significantly wider than the Zacks Consensus Estimate of 46 cents and the year-ago loss of 50 cents.
Revenues in the quarter came in at $13.0 million, significantly down from $23.6 million in the year-ago quarter and below the Zacks Consensus Estimate of $18.3 million.
Quarter in Detail
Momenta’s top line comprises product revenues of $11.8 million earned from Sandoz’s sales of Glatopa, a generic version of Copaxone (20 mg), compared with $19.1 million in the year-ago quarter. The decrease was a result of lower sales due to market decline and Mylan’s entry into the Copaxone market.
Research and development revenues came in at $1.3 million compared with $4.4 million in the year-ago quarter. The decrease was primarily due to lower revenues recognized from the upfront payment from Mylan compared with the amount recognized in the 2017 period and lower reimbursable expenses for the complex generic programs.
Research and development expenses decreased to $31.3 million from $39.1 million in the year-ago quarter due to a decrease in external R&D expenses for M923. General and administrative expenses were roughly flat at $22.5 million.
During the second quarter, Momenta entered into a contract amendment to an agreement with Human Genome Sciences, Inc., the supplier of product for M923. Per the terms of the agreement, Momenta will pay the latter $30.0 million for the purchase of product batches for M923 through 2022.
Pipeline Updates
In June 2018, Momenta’s partner, Sandoz informed its customers and the FDA that it will be discontinuing the supply of the generic version of Lovenox injection, for the prevention and treatment of deep vein thrombosis, developed in collaboration with Sandoz.
Meanwhile, Momenta and Mylan plan to initiate a patient clinical trial of M710, a proposed biosimilar of Regeneron’s (REGN - Free Report) Eylea, shortly.
The Biologics License Application (“BLA”) for Momenta’s M923, a biosimilar version of Humira, is also ready to be filed with the FDA. However, the filing of the BLA is dependent on the outcome of the company’s ongoing strategic review.
Momenta’s novel auto-immune portfolio includes M230, a Selective Immunomodulator of Fc receptors (SIF3); M281, an anti-FcRn monoclonal antibody; and M254.
Momenta successfully completed a phase I single ascending dose study in healthy volunteers for M281. The company is planning two phase II proof of concept clinical trials in the fourth quarter of 2018, pending regulatory feedback.
Meanwhile, Momenta and collaboration partner CSL began dosing healthy volunteers in the phase I trial to evaluate the safety and tolerability of M230. The study is expected to be completed in 2019.
Momenta completed the IND-enabling toxicology study of M254 and is targeting the initiation of a phase I/II proof of concept study in late 2018 or early 2019, pending regulatory feedback.
Our Take
Momenta’s second-quarter results were dismal as the company lost market share for Glatopa 20 mg. While the FDA approval of Glatopa 40 mg should relieve Momenta, competition will limit market share gains for the company as Mylan has already won the FDA’s approval for a generic version of Teva Pharmaceuticals’ (TEVA - Free Report) Copaxone 40 mg. The company continues to face fierce competition due to growing pricing pressure from Mylan and Teva.
Momenta Pharmaceuticals, Inc. Price and Consensus
Momenta Pharmaceuticals, Inc. Price and Consensus | Momenta Pharmaceuticals, Inc. Quote
Hence, investors will now mainly focus on the outcome of the strategic review announced earlier this year to address the revenue uncertainty related to the late launch of Glatopa 40 mg and the funding challenges for advancing its broad portfolio. The company is evaluating options for its biosimilars business and might have to sell the business to focus on its novel drug candidates for autoimmune indications.
Zacks Rank
Momenta currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>